Related Experiment Video
Updated: Feb 11, 2026
07:49
Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach
Published on: July 21, 2023
2.0K
New percutaneous interventions in heart failure.
Elisabetta Moscarella1, Salvatore Brugaletta1, Manel Sabaté2
1Service of Cardiology, August Pi i Sunyer Institute for Biomedical Investigation (IDIBAPS), Clínic Hospital, Barcelona, Spain.
Minerva Cardioangiologica
|April 14, 2018
Summary
New transcatheter devices offer innovative treatment options for chronic heart failure (HF), addressing persistent high mortality despite existing therapies. This review explores current and emerging interventional HF devices for conditions like mitral regurgitation and diastolic dysfunction.
Area of Science:
- Interventional Cardiology
- Cardiovascular Devices
- Heart Failure Management
Background:
- Chronic heart failure (HF) significantly contributes to global mortality and morbidity.
- Increasing HF prevalence is linked to improved acute cardiac care, leading to reduced immediate mortality but higher long-term burden.
- HF presents as reduced ejection fraction (HFrEF) or preserved ejection fraction (HFpEF), often indicating diastolic dysfunction.
Purpose of the Study:
- To review current and investigational transcatheter implantable devices for chronic heart failure (HF).
- To summarize treatment alternatives for valvular issues like mitral and tricuspid regurgitation in HF patients.
- To explore novel device-based strategies for left ventricular (LV) restoration and left atrial decompression.
Main Methods:
- Systematic review of approved and investigational interventional HF devices.
- Analysis of device mechanisms for treating HF complications such as valvular regurgitation and diastolic dysfunction.
- Evaluation of emerging technologies including partitioning and shunting devices.
Main Results:
- Several transcatheter devices are approved or under investigation for HF management.
- Interventional options exist for mitral and tricuspid regurgitation, improving HF symptoms.
- Novel devices aim for LV restoration and left atrial pressure reduction.
Conclusions:
- Transcatheter device therapy represents a rapidly evolving frontier in managing chronic heart failure.
- These devices offer potential improvements for patients with HFrEF and HFpEF, particularly those with valvular disease.
- Further research and clinical trials are essential to establish the role of new interventional HF devices.
Related Concept Videos
01:30Heart Failure VII: Nursing Interventions
545
The first step in nursing management of a patient with heart failure involves thoroughly assessing the patient's medical history.Subjective Data: Obtain the patient's medical history of coronary artery disease, hypertension, myocardial infarction, and symptoms like dyspnea, orthopnea, and paroxysmal nocturnal dyspnea.Objective Data: Conduct a physical examination to identify findings such as jugular vein distention, pulmonary crackles, tachycardia, murmurs, peripheral edema, and vital signs,...
545
01:29Heart Failure II: Pathophysiology
1.0K
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.0K
01:17Pathophysiology of Heart Failure
4.0K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
4.0K
01:27Heart Failure I: Introduction
951
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
951
01:22Heart Failure VI: Adjunct Therapies
395
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
395
01:22Heart Failure Drugs: Diuretics
1.0K
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
1.0K